Transcription and protein profiling of whole blood and serum from natalizumab treated patients with developed progressive multifocal leukoencephalopathy.

Trial Profile

Transcription and protein profiling of whole blood and serum from natalizumab treated patients with developed progressive multifocal leukoencephalopathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Progressive multifocal leukoencephalopathy
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top